E’ il “Fibroscan”, per individuare patologie croniche
Risultati per: Screening e la diagnosi del cancro al seno
Questo è quello che abbiamo trovato per te
Al Parini nuovo strumento per diagnosi malattie epatiche
E’ il “Fibroscan”, per individuare patologie croniche
Screening Mammography for 40-Year-Old Women
This Viewpoint discusses the potential risks and benefits for starting screening at 40 rather than 50 years of age and whether clinicians or patients should decide based on risk rather than age.
Comments on “Risk of Cancers Proximal to the Colon in Fecal Immunochemical Test Positive Screenees in a Colorectal Cancer Screening Program”
Clinical Application of New Risk-Based Cancer Screening in Patients With Dermatomyositis
Dermatomyositis (DM) is an autoimmune disease of unknown etiology belonging to the family of idiopathic inflammatory myopathies (IIMs). The association of DM with cancer has long been established and there is increased prevalence of various cancers, including breast, ovarian, colorectal, lung, nasopharyngeal, and lung cancers. Cancers in IIMs are frequently diagnosed at later stages, making cancer the leading cause of death in adults with IIMs. Despite this increased prevalence of and worse prognosis associated with underlying cancer, screening recommendations for cancer detection in patients with IIM have been debated for many years, with wide variability in screening practices. This lack of clarity regarding ideal cancer screening practices became further complicated with the expanding knowledge of myositis-specific antibodies and their association with cancer risk, which raised the question of how to apply serology status to screening protocols. Finally, there has been a need to balance early cancer detection with avoidance of unnecessary screening procedures, given that cancer prevalence is best estimated at only 15% to 25% of patients with DM. Thus, applying screening to all patients is associated with many unnecessary procedures.
How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening?
This Viewpoint explores how guideline groups can come together to agree on a framework that produces clear and unified recommendations.
Application of Risk-Based Cancer Screening in Patients With Dermatomyositis
This cohort study investigates the performance of the International Myositis Assessment and Clinical Studies Group cancer screening recommendations in a community setting.
Comment on “Risk of Cancers Proximal to the Colon in Fecal Immunochemical Test Positive Screenees in a Colorectal Cancer Screening Program”
Reevaluating Confounders and Risk Interpretation in FIT-Positive Cancer Screening
Uno studio per superare la farmaco resistenza nel tumore al seno
Ricerca del Cro di Aviano pubblicata sul Journal of Pathology
Uno studio per superare la farmaco resistenza nel tumore al seno
Ricerca del Cro di Aviano pubblicata sul Journal of Pathology
Il 20% degli italiani non riceve la chiamata per gli screening
Indagine sui pazienti, 1 su 5 rinuncia per orari o liste d’attesa
Malattie rare delle ossa, fino a 10 anni per una diagnosi corretta
Medici e pazienti, ‘più formazione e rendere le terapie disponibili per tutti’
Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer
Annals of Internal Medicine, Ahead of Print.
Candiolo, in un anno 26 milioni per cura e ricerca sul cancro
Illustrato Bilancio sociale. Parte secondo lotto della Biobanca
Candiolo, in un anno 26 milioni per cura e ricerca sul cancro
Illustrato Bilancio sociale. Parte secondo lotto della Biobanca